Fate Therapeutics, Inc. (FATE)
1.24
-0.06
(-4.62%)
USD |
NASDAQ |
Apr 29, 16:00
1.25
+0.01
(+0.81%)
After-Hours: 07:17
Fate Therapeutics EPS Diluted (Quarterly) : -0.2715 for Dec. 31, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.596 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
| Savara, Inc. | -0.1341 |
| BioMarin Pharmaceutical, Inc. | -0.2423 |
| Imunon, Inc. | -1.292 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.37M |
| Revenue (Quarterly) | 1.369M |
| Total Expenses (Quarterly) | 33.74M |
| Enterprise Value | 18.36M |
| Gross Profit Margin (Quarterly) | -123.7% |
| Profit Margin (Quarterly) | -2.36K% |
| Earnings Yield | -92.56% |
| Normalized Earnings Yield | -92.68 |